Irinotecan dose reduction in metastatic colorectal cancer patients with ...

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with ...

(PDF) Irinotecan in metastatic colorectal cancer: Dose intensification ...

(PDF) Early Magnesium Reduction in Advanced Colorectal Cancer Patients ...

Toxicity with irinotecan dose reduction and UGT1A1 status ...

(PDF) UGT1A1*28 genotype and irinotecan dosage in patients with ...

Study on Cetuximab and Irinotecan for Patients with Metastatic ...

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients ...

Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer ...

(PDF) Cellular irinotecan resistance in colorectal cancer and ...

Irinotecan plus bevacizumab improves metastatic colorectal cancer ...

Treatment strategies for the metastatic colorectal cancer patients ...

Efficacy and safety of high doses of irinotecan in patients with ...

(PDF) Regorafenib plus FOLFIRI with irinotecan dose escalated according ...

(PDF) Regorafenib plus FOLFIRI with irinotecan dose escalated according ...

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to ...

(PDF) Dose adjustment of irinotecan based on UGT1A1 polymorphisms in ...

(PDF) The efficacy of irinotecan supplementation for colorectal cancer ...

Comparison of short-term effects between the irinotecan dose reduction ...

(PDF) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal ...

Irinotecan is a Topoisomerase I Inhibitor for Colorectal Cancer ...

(PDF) Colorectal cancer metastasis resectability after treatment with ...

(PDF) Irinotecan toxicity during treatment of metastatic colorectal ...

(PDF) A phase I trial of lomeguatrib and irinotecan in metastatic ...

Transarterial Treatment of Colorectal Cancer Liver Metastases with ...

(PDF) Cost-effectiveness of cetuximab in combination with irinotecan ...

(PDF) Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic ...

Frontiers | Clinical Outcomes Among Patients With Metastatic Pancreatic ...

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal ...

Table 1 from Prognostic factors for metastatic colorectal cancer ...

(PDF) Biweekly Raltitrexed in Combination with Irinotecan (RIR) as ...

A phase II study of guadecitabine combined with irinotecan vs ...

Figure 1 from Clinical Outcomes of Patients with Peritoneal Metastasis ...

Effect of drug metabolizing enzymes and transporters in Thai colorectal ...

Real-World Evidence on Second-Line Treatment of Metastatic Colorectal ...

(PDF) Biweekly Raltitrexed Combined With Irinotecan as Second-Line ...

(PDF) A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in ...

(PDF) Phase II study of weekly irinotecan and capecitabine treatment in ...

(PDF) Clinical Outcomes of Patients with Peritoneal Metastasis-Only ...

(PDF) Transarterial treatment of colorectal cancer liver metastases ...

(PDF) Irinotecan plus raltitrexed as second-line treatment in locally ...

(PDF) Reduced incidence of infusion-related reactions in metastatic ...

(PDF) Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First ...

(PDF) Elucidating the role of pharmacogenetics in irinotecan efficacy ...

(PDF) FOLFIRI and regorafenib combination therapy with dose escalation ...

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for ...

Prognostic advantage of irinotecan dose escalation according to uridine ...

Retrospective analysis of the impact of dose delay and reduction on ...

FOLFIRI and regorafenib combination therapy with dose escalation of ...

(PDF) Oxaliplatin, irinotecan and capecitabine as first-line therapy in ...

(PDF) Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose ...

Fluoropyrimidine and irinotecan chemotherapy in the treatment of ...

Various irinotecan dose levels (DL) and dose-limiting toxicities (DLTs ...

Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in ...

Mean RDI (%) of irinotecan dose per regimen. Boxplots of mean ...

Criteria for irinotecan dose adjustment due to liver toxicity ...

Metastatic colorectal cancer: mechanisms and emerging therapeutics ...

(PDF) Irinotecan: a key chemotherapeutic drug for metastatic colorectal ...

(PDF) A dose finding and pharmacokinetic study of capecitabine in ...

PPT - Management of Metastatic Colorectal Cancer: Focus on Targeted ...

Criteria for irinotecan dose adjustment due to liver toxicity ...

(PDF) Irinotecan plus Fluorouracil and Leucovorin for Metastatic ...

Correlation between UGT1A1 genetic polymorphisms and irinotecan dose ...

(PDF) Randomized phase III trial in elderly patients comparing LV5FU2 ...

Full article: Real-World Outcomes Associated with Liposomal Irinotecan ...

PPT - Management of Metastatic Colorectal Cancer: Focus on Targeted ...

PPT - Management of Metastatic Colorectal Cancer: Focus on Targeted ...

Irinotecan combined with fluorouracil compared with fluorouracil alone ...

Management of Metastatic Colorectal Cancer - Clinical Tree

Partnering bevacizumab with irinotecan as first line-therapy of ...

Soluble irinotecan as a treatment for colorectal cancer - Medivizor

(PDF) A phase II study of S-1 plus irinotecan and oxaliplatin in ...

Real-World Evidence on Second-Line Treatment of Metastatic Colorectal ...

(PDF) Phase I dose-escalation trial of irinotecan with continuous ...

Figure 1 from Irinotecan toxicity during treatment of metastatic ...

(PDF) A phase 2 study of panitumumab with irinotecan as salvage therapy ...

(PDF) Phase III Comparison of Two Irinotecan Dosing Regimens in Second ...

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and ...

Efficacy and safety of regorafenib plus FOLFIRI with UGT1A1 genotyping ...

(PDF) Extended RAS Analysis of the Phase 3 EPIC Trial: Irinotecan ...

Irinotecan for colorectal cancer: a small step forward - The Lancet

Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with ...

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and ...

Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with ...

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan ...

(PDF) Chemotherapy for metastatic colon cancer: No effect on survival ...

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment ...

Table 2 from High-Dose FOLFIRI plus Bevacizumab in the Treatment of ...

(PDF) Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and ...

(PDF) Improved Progression-Free Survival in Irinotecan-Treated ...

CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment ...

(PDF) S-1 plus irinotecan and oxaliplatin for the first-line treatment ...

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated ...

(PDF) A genotype-directed phase I-IV dose-finding study of irinotecan ...

(PDF) Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose ...

Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy ...

Cetuximab And Chemotherapy As Initial Treatment For Metastatic ...

(PDF) A randomised phase II multicentre trial of irinotecan (CPT-11 ...

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated ...

(PDF) Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with ...

Table 1 from Impact of irinotecan and oxaliplatin on overall survival ...

Clinical data of the seven enrolled UGT1A1*28/*28 patients. | Download ...

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin ...

Table 2 from Comparison of UGT1A1 Polymorphism as Guidance of ...

Clinical data of the seven enrolled UGT1A1*28/*28 patients. | Download ...

(PDF) Effectiveness and Cost-Utility Analysis of Different Doses of ...

(PDF) Bevacizumab May Overcome Clinical Tumor Drug Resistance to ...

(PDF) Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for ...

Study Comparing Regorafenib and Regorafenib-Irinotecan Combination for ...

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen ...

Figure 1 from Comparison of UGT1A1 Polymorphism as Guidance of ...

(PDF) Efficacy and quality of life for FOLFOX/bevacizumab +/− ...

(PDF) Determination of the UGT1A1 polymorphism as guidance for ...

(PDF) Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis ...

(PDF) Intermittent or Continuous Panitumumab Plus Fluorouracil ...

(PDF) Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First ...

Frontiers | Effectiveness and Cost-Utility Analysis of Different Doses ...

Oncology Letters

Oncology Letters

New Colon Chemotherapy